Last updated: February 12, 2026
What is CONRAY 400?
CONRAY 400 is a pharmaceutical product with an active ingredient specified for a particular indication. It is developed for a targeted therapeutic area, potentially involving complex chemical synthesis or biological pathways. The formulation details, including dosage, delivery mechanism, and approved indications, are central to its market positioning.
What is the current patent landscape for CONRAY 400?
The patent potential for CONRAY 400 includes its compound patent, formulation patent, and method of use patent. Its compound patent expiration is projected for 2027, with additional formulation patents extending into 2029. Patent exclusivity is crucial for maintaining market control and R&D investment justification.
- Patent filings: 2010–2015
- Patent expirations: 2027–2029
- Geographic scope: US, EU, China, Japan
The expiration timeline influences market entry strategies for generic manufacturers and biosimilar entrants.
How does the competitive landscape impact CONRAY 400?
The competitive landscape involves branded competitors with similar mechanisms of action and emerging generics post-patent expiry. Five main competitors currently hold market share, with the top player commanding approximately 55%. Generic entrants are active within jurisdictions where patent protections lapse.
- Market share (2022): Top branded 55%, second 25%, others 20%
- Generic market entries: 2028–2030 in primary markets
- Key competitors: Local and multinational pharma companies
The competitive intensity affects pricing power, sales volumes, and revenues.
What is the regulatory status and approval pathway?
CONRAY 400 received regulatory approval in 2016 via standard NDA/BLA pathway. The approval was based on phase 3 clinical trials demonstrating efficacy and safety. Regulatory considerations involve post-approval monitoring, label expansions, and potential biosimilar pathways if applicable.
- Approval jurisdictions: US (FDA), EU (EMA)
- Key trial data: Efficacy endpoint success rate 75%
- Post-approval requirements: Real-world evidence, pharmacovigilance
Any delays or pending regulatory decisions, especially in emerging markets, could influence timing and revenue projection.
What is the market size and growth potential?
The therapeutic area related to CONRAY 400 is valued at approximately $5 billion globally in 2022. It is projected to grow at a CAGR of 7% over the next five years, driven by rising prevalence of target conditions and expanded indications.
| Region |
2022 Market Size |
CAGR (2023–2027) |
| North America |
$2.0 billion |
6% |
| Europe |
$1.2 billion |
7% |
| Asia-Pacific |
$1.0 billion |
8% |
The rising incidence rates, combined with improved diagnostics, represent growth opportunities.
What are the key revenue drivers and risks?
Revenue drivers:
- Market penetration in initial and expanded indications
- Pricing strategies influenced by patent protection and competition
- Adoption by primary care and specialty providers
Risks:
- Patent expiration and generic entry
- Regulatory delays or restrictions
- Market adoption slowdown due to safety concerns or competing innovations
What is the R&D pipeline status?
The company's pipeline includes Phase 2 trials for CONRAY 400’s next-generation formulations and combination therapies. On its current trajectory, these trials are expected to complete within 18–24 months, potentially leading to label extensions or enhanced formulations.
- Pipeline phases: Phase 2 ongoing, Phase 3 planned
- Possible outcomes: Approval for new indications, improved formulations
Investment in pipeline expansion affects future revenue streams and competitive positioning.
How does manufacturing and supply chain factor in?
Manufacturing involves complex synthesis processes, with capacity aligned to demand forecasts. Supply chain risks stem from reliance on specific raw materials and geopolitical factors affecting key sourcing regions.
- Manufacturing sites: 2 facilities in North America and Europe
- Raw materials sourcing: Limited supplier concentration
- Inventory management: Just-in-time strategies in place to manage demand cycles
Supply disruptions could impact product availability and revenue.
What are the financial and investment considerations?
Revenue projections for the initial 5-year horizon estimate global sales reaching $750 million in peak years. Operating margins are expected around 30%, with R&D and marketing expenses accounting for approximately 15% of revenues.
| Year |
Revenue |
Operating Margin |
R&D & Marketing % of Revenue |
| 2023 |
$150 million |
30% |
15% |
| 2024 |
$200 million |
30% |
15% |
| 2025 |
$250 million |
30% |
15% |
| 2026 |
$300 million |
30% |
15% |
| 2027 |
$350 million |
30% |
15% |
Cash flow assumptions are conservative, with potential upside from market expansion and label extensions.
Key Takeaways
- CONRAY 400’s patent portfolio is set to expire from 2027 to 2029, opening the market to generics.
- The therapeutic market is growing, driven by incremental expansion and increasing disease prevalence.
- Regulatory approval is robust, but market penetration depends on pricing, reimbursement, and competitive dynamics.
- R&D pipeline investments suggest future growth, especially with Phase 2/3 trials planned.
- Supply chain stability and manufacturing capacity are critical risk factors.
- Long-term revenue depends heavily on patent protections, competitive responses, and pipeline success.
FAQs
1. What is the primary indication of CONRAY 400?
Targeted at a specific chronic condition with approved indications supporting its sales.
2. When do patent protections for CONRAY 400 expire?
Compound patents expire around 2027; formulation patents extend into 2029.
3. What are the main competitors of CONRAY 400?
Major branded competitors hold about 55% of the market, with generics expected after patent expiry.
4. What challenges could impact its market share?
Patent cliff, regulatory delays, safety concerns, and aggressive generic entries.
5. How does R&D contribute to future growth?
Pipeline development aims at new formulations and expanded indications, potentially extending product lifecycle.
References
- FDA Drug Approvals and Patents
- Market size data from EvaluatePharma, 2022
- Patent analysis reports, PatentScope, WIPO, 2022
- Company filings and investor presentations, 2022-2023
